Medesis Pharma S.A.

Equities

ALMDP

FR0010844464

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 06:39:21 2024-05-02 am EDT			5-day change	1st Jan Change
1.245 ^EUR	+0.40%		-18.09%	+43.43%

2023	Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	MEDESIS : Invest Securities confirms its recommendation	CF

Medesis Pharma : Résiliation du contrat avec la société NICE & GREEN S.A.

March 19, 2024 at 01:10 pm EDT

Medesis Pharma : Résiliation du contrat avec la société NICE & GREEN S.A.

19 Mar 2024 18:01 CET

Issuer

MEDESIS PHARMA S.A.

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1237633_CP_NG_19_mars_2024.pdf

Source

MEDESIS PHARMA

Provider

Les Echos

Company Name

MEDESIS PHARMA S.A.

ISIN

FR0010844464

Symbol

ALMDP

Market

Euronext Growth

Attachments

Original Link
Permalink

Disclaimer

Medesis Pharma SA published this content on 19 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 March 2024 17:09:03 UTC.

Latest news about Medesis Pharma S.A.

Medesis Pharma S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-27	CI
MEDESIS : Invest Securities confirms its recommendation	23-10-06	CF
Medesis Pharma: selected for the Prix Galien USA	23-08-04	CF
MEDESIS : Invest Securities maintains its recommendation	23-07-12	CF
MEDESIS : Invest Securities confirms its recommendation	23-07-07	CF
Global markets live: Gamestop, Lucid, Meta Platforms, Vodafone, Nestlé...	23-06-08
Global markets live: Shell, Netflix, Nike, Ocado, Tesla...	23-03-31
Global markets live: Blackberry, Meta Platforms, Rivian, GM...	23-03-07
Medesis Pharma Soars 16% On New Grant For Investigational Huntington's Disease Drug	22-07-20	MT
Medesis Pharma Up 65% After Asking Funds For Nuclear Contamination Drugs	22-04-05	MT
Medesis Pharma Publishes an Information Note on the Three Future Drugs in Development for the Protection of Large Populations Contaminated After A Civil or Military Nuclear Accident	22-04-05	CI
Medesis Pharma Wins COVID-19 Drug Trial Approval In Brazil	21-11-22	MT
Global markets live: Ford, Walmart, Apple, Volkswagen, Tesla...	21-09-02
Global markets live: Nvidia, Microsoft, Dell, Apple, Uber...	21-08-27
Medesis Pharma S.A.(ENXTPA:ALMDP) added to Next Biotech Index	21-02-15	CI
Medesis Pharma S.A. has completed an IPO in the amount of €7.350317 million.	21-02-09	CI
Medesis Pharma S.A. has filed an IPO in the amount of €7.350317 million.	21-01-26	CI
Medesis Pharma SA announced that it has received €0.04 million in funding	15-10-25	CI
Medesis Pharma SA announced that it expects to receive €1 million in funding.	15-09-17	CI

Chart Medesis Pharma S.A.

Duration

Period

More charts

Company Profile

Medesis Pharma S.A. is specialized in the research and development, based on a breakthrough technology (AONYS®) for the delivery of therapeutic molecules, of drugs to treat diseases for which there is no effective treatment. The company's portfolio includes a drug candidate used to optimize cancer radiotherapy, 2 drug candidates used in the treatment of neurodegenerative diseases (Alzheimer's disease and Huntington's disease) and 2 drug candidates used in the treatment of radioactive contamination following a civil or military nuclear accident (Plutonium decorporation and cesium decorporation).

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEDESIS PHARMA S.A.	+43.43%	5.87M
VERTEX PHARMACEUTICALS INCORPORATED	-1.39%	104B
REGENERON PHARMACEUTICALS, INC.	+6.84%	97.47B
ARGENX SE	+5.71%	22.25B
BIONTECH SE	-12.97%	21.68B
GENMAB A/S	-9.70%	18.2B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-9.90%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+8.44%	14.39B
SAREPTA THERAPEUTICS, INC.	+39.03%	12.37B

Bio Therapeutic Drugs